Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (stock code: 02196) has issued a notice announcing plans for a first extraordinary general meeting on 27 February 2026 at 1:30 p.m., to be held at Sky Fortune Boutique Hotel Shanghai. The agenda will focus on twelve special resolutions related to the proposed spin-off of Fosun Adgenvax and the listing of its H shares on the Main Board of the Hong Kong Stock Exchange.

Key resolutions include assessing the spin-off’s compliance with relevant laws, examination of the commercial rationale and feasibility, and ensuring the company’s independence and operating capability after the spin-off. The proposed plan also addresses the protection of shareholders’ and creditors’ rights, the completeness of statutory procedures, and the authorization to the board to handle all related matters. Additionally, an assured entitlements arrangement to the company’s H shareholders in connection with the spin-off is outlined in the resolutions.

The company has noted that voting on all resolutions is open to holders of overseas listed foreign shares (H Shares). Proxy forms and supporting documents must be submitted to the Hong Kong share registrar at least 24 hours before the meeting. Shareholders who submit proxy forms will retain the right to attend and vote at the meeting in person.